There are no current FDA approved medications to treat BED specifically As long as the client meets reasonable criteria for a GLP-1 prescription, it is the clients choice as to whether they want to continue to use this medication while in BED treatment
Studies of GLP-1 receptor agonists show that consistency of dosing correlates directly with weight reduction velocity: patients with 90% or higher adherence lose 1215% of baseline body weight over six months, while those with 70% adherence drop to 810% loss in the same timeframe
10.3389/fphar.2020.618787 62 Jamali-RaeufyN.KardgarS.BaluchnejadmojaradT.RoghaniM.GoudarziM
Canadas drug agency recently approved Zepbound (weekly tirzepatide) for obesity, reflecting these results
Moreover, conjugated with targeting moieties such as specific antibodies and ligands, metal-based NPs can be actively targeted to the disease sites by recognizing and binding to the corresponding membrane proteins (Meka et al., 2019
The goal is to saturate the area around the damaged fascia, not to inject directly into the ligament itself, which could cause further injury
